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Background: Management of difficult to wean patients is a dilemma for health care system. Recently published
studies demonstrated efficacy of donepezil to counteract respiratory depression in sleep apnea. However, to the
best of our knowledge, pharmaceutical interventions with donepezil to facilitate weaning have not been tested so
far. Therefore in the present study, we evaluated the efficacy of using donepezil on weaning course in difficult to
wean patients.
Methods: In this non-randomized interventional clinical study, difficult to wean patients with prior inappropriately
depressed respiratory responses were included from two referral intensive care units (ICU) in Iran. Patients with
another potentially reasons of weaning failure were excluded from the study. Donepezil was started for eligible
patients at dose of 10 mg daily for 2–4 weeks. For the primary outcomes, arterial blood gas (ABG) parameters were
also measured before and after intervention to evaluate the possible effects of donepezil on them. In addition,
weaning outcomes of patients were reported as final outcome in response to this intervention.
Results: Twelve out of 16 studied patients experienced successful results to facilitate weaning with donepezil
intervention. The mean duration of donepezil treatment until outcome measurement was 12 days. There were not
any significant differences in ABG parameters among patients with successful and failed weaning trial on day of
donepezil initiation. However after donepezil intervention, mean of PCO2 and HCO3 decreased in patients with
successful weaning trial and mean of PCO2 increased in those with weaning failure.
Conclusions: Reduced central respiratory drive was infrequently reason of failed weaning attempts but it must be
considered especially in patients with hypercapnia secondary to inefficient gas exchange and slow breathing. Our
results in the clinical setting suggest that, the use of donepezil can expedite weaning presumably by stimulation of
respiratory center and obviate the need to re-intubation in cases of respiratory drive problem in difficult to wean
patients. We suggest decrease PCO2 and HCO3 during donepezil steady could be valuable predictors for positive
response to donepezil intervention.Background
Difficult weaning is a common problem of patients in
whom weaning trials were attempted [1]. Since, 26% of
medical and surgical patients were considered difficult-
to-wean in a prospective cohort study [2]. Similarly,
another prospective cohort study found that the incidence
of difficult weaning was 39% among patients who needed
mechanical ventilaion for more than 12 hours [3].* Correspondence: farsaei@pharm.mui.ac.ir
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unless otherwise stated.Both prolonged weaning and duration of mechanical
ventilation are associated with increased risk of mortality.
Therefore, difficult weaning is an important challenge for
critically ill patients with mechanical ventilation support
[4]. Management of patients who are difficult-to-wean is
based on identification and correction of potential causes
related to ventilator dependency [5].
Although impaired respiratory drive is an uncommon
cause of weaning failure, but its important role should
be highlighted if any definite reason is not found for
weaning failure [1]. Therefore, treatment targeting the
respiratory drive can be helpful in facilitating weaning ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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as caffeine, aminophylline and doxapram have been used
effectively to increase central respiratory drive and subse-
quently weaning from mechanical ventilation and avoiding
post-extubation apnea in preterm infants [7-9]. In
addition, some studies showed beneficial effects of
cholinergic drugs like donepezil to stimulate respiratory
drive [10,7].
Some advances in understanding the role of central
cholinergic modulation in the process of respiration
provide a pharmacological basis for explaining beneficial
effects of cholinergic drugs as therapeutic agents for disor-
ders related to neural control of breathing [10]. Donepezil
is cholinergic drug which reversibly and noncompetitively
inhibits centrally-active acetyl cholinesterase [11]. It was
first introduced for Alzheimer treatment but many studies
showed efficacy and safety of donepezil for different clinical
problems such as cognitive impairment resulting from
severe traumatic brain injury [12-14]. Nausea, diarrhea,
insomnia and infection were reported the most prevalent
adverse reactions of donepezil with prevalence of less than
20% in high doses of donepezil [15].
Moreover, findings of conducted animal studies indicated
the beneficial effect of systemically administered donepezil
to counteract respiratory depression in anesthetized rabbits
[16,17]. Recently published clinical studies showed
donepezil may improve sleep apnea [18,19]. As a result, it
seems donepezil is safe and may be effective medication to
stimulate respiratory drive. To the best of our knowledge,
pharmaceutical interventions with donepezil in difficult-to-
wean patients have not been tested so far. Therefore, in the
present study we hypothesized that using donepezil could
facilitate weaning course in difficult-to-wean patients.
Methods
This is an interventional non-randomized clinical study ap-
proved by medical ethics committee of Isfahan University
of Medical Sciences (Code Number: 292232) and con-
ducted in the intensive care units (ICUs) of two referral
hospitals in Iran (Alzahra and Imam reza hospitals).
Intubated patients who failed the first spontaneous
breathing trial (SBT) on weaning trial and required up
to three SBTs or 7 days to pass a SBT were defined as
difficult-to-wean. Difficult-to-wean patients with prior
inappropriately depressed respiratory responses when
removed from the ventilator were considered eligible
to enter in this study.
According to clinical judgment of intensivist, when other
possible reasons of weaning failure such as electrolytes and
acid–base disorders were ruled out, depressed respiratory
response could be considered the cause of this failure.
Since electrolytes and acid–base imbalances (in particular
metabolic alkalosis from volume depletion which promoted
hypoventilation) could interfere in weaning process, we didour best to control and maintain normal ranges of serum
electrolytes and nutritional support in this study and
preserve the pH less than 7.45 during the time of active
weaning [20].
Patients with unconsciousness and need for sedation
or hypothyroidism were excluded from this study.
A continuous electrocardiograms (ECG), heart rate,
mean arterial blood pressure, and oxygen saturation
were also monitored during SBT. Therefore, patients with
weaning-related myocardial ischemia or hemodynamic
instability were excluded from the study to omit the
potentially negative effects of these confounding factors
on weaning failure [21]. Treatment with other potentially
respiratory stimulants such as doxapram and medroxy-
progesterone was additional criterion to exclude patients
from this study.
Donepezil was started for eligible patients according to
inclusion and exclusion criteria at dose of 10 mg daily.
Because time to steady state for donepezil was expected
15 days [22], donepezil administration was continued at
least for 2 weeks and patients were followed up daily
during this period and evaluated for readiness of weaning
and other endpoints of the study. If weaning was failed
during first two weeks, patients would be assessed again
for another potential barrier to extubation. In cases with
strong clinical suspicion of central respiratory drive
problem during weaning, donepezil was continued for
another two weeks until 4-week duration of donepezil
treatment [23].
For the primary outcomes of the study, oxygenation
variables such as partial pressures of oxygen (PO2) and
carbon dioxide (PCO2), pH and hemoglobin oxygen
saturation (SO2) were measured on day of donepezil
initiation and on day of outcome evaluation. Moreover,
weaning outcomes of patients were reported as final
outcome in response to this intervention. Thereafter
for statistical analysis patients were categorized in two
groups: patients with successful or failure weaning
and then oxygenation variables mentioned above were
compared between two groups.
Statistical analysis: Descriptive and statistical analyses
were performed. The distribution of continuous variables
was assessed by the Kolmogrov-Smirnov test, and
continuous data were expressed as mean ± SD. The
Mann–Whitney U test and independent sample t-tests
were used to assess differences in quantitative data of
patients’ characteristics for nonparametric and parametric
variables, respectively. For categorical data expressed as
percentage, chi-squared test was applied.
Results
Eighteen difficult-to-wean patients with suspicion of de-
pressed respiratory response (62 ± 18 years old) were in-
cluded in this study and finally 16 patients completed
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enrolled subjects died before any evaluations, therefore
data were not applicable to evaluate weaning outcome of
them (Figure 1). Characteristics of the patients were
summarized in Table 1.
The study patients had been on mechanical ventilation
for 32 ± 21 days prior to study enrollment. In addition,
more than 80% of patients had been failed weaning trial
more than 2 times before enter to study. Among 16
studied patients, 13 patients had pneumonia, whereas;
30% of them experienced concomitant acute exacerbation
of COPD. Pulmonary edema was also reported in 3
patients (Table 1).
The results showed 12 out of 16 patients experienced
successful weaning during donepezil intervention. However,
in one of the successful weaning trial, re-intubation was
occurred during 24 hours and therefore considered as
final unsuccessful weaning outcome.
Therefore, 11 patients were categorized as successful
weaning and remained patients were classified in unsuc-
cessful weaning group. In comparison of these two groups
of patients (successful or failure weaning), there were not
any significant differences in age, duration of mechanical
ventilation and number of failed weaning trial before
donepezil initiation (p-value > 0.05) (Table 2).
The effects of donepezil on arterial blood gas (ABG)
were also evaluated on day of donepezil initiation and
on day of outcome measurement. Variations in arterial PH,
PO2, PCO2, HCO3 and oxygen saturation were demon-
strated in part A, B, C, D and E of Figure 2 respectively.
Results showed patients had no evidence of primary
metabolic alkalosis at weaning time.
According to independent sample t-test, there were not
any significant differences in ABG parameters between
successful and unsuccessful weaning patients on day of
donepezil initiation (p-value > 0.05). In patients with suc-
cessful weaning trial, paired sample analyses revealedDonepezil was prescribed for 18 diff
with suspicion of depressed respiratory
inclusion criteri
16 patients completed
5 patients experienced weaning failure
Figure 1 Flow diagram of the patients received donepezil during stud
completed the study experienced successful weaning in our study.mean of PCO2 and HCO3 decreased, whereas mean of
PO2 and PO2 saturation increased after donepezil inter-
vention. Although, in those with failed weaning, mean of
PCO2 increased after donepezil intervention. However
none of these statistical analyses were significant (Table 3).
Discussion
This present study was performed in difficult-to-wean
patients with potential respiratory drive problems which
caused repeatedly failing spontaneous breathing attempts.
Donepezil administration in our study enabled successful
SBT and weaning in nearly 70% of patients. Our patients
manifested hypercapnia and hypopnea when removed from
the ventilator in prior weaning trials which promoted the
probability of reduced ventilator central drive before done-
pezil initiation. Since, we initially could find neither revers-
ible causes for repeated failure to prior weaning trials, nor
any contraindication for the use of donepezil, we empirically
used donepezil to facilitate weaning in these patients.
According to recent systematic review and meta-analysis,
10 mg donepezil was well tolerated without any life threat-
ening effect [24]. In addition, regarding to the long half-life
of donepezil (70 hours) it is unlikely that adverse reac-
tions of donepezil occurs in first days of its initiation [25].
Therefore, deaths of two patients in the initial days of
donepezil intervention might be related to poor clinical
condition of them not donepezil adverse reactions.
Also it should be mentioned that no related adverse
reaction of donepezil was reported during follow up
of our study.
Etiologies of failures upon removal from the ventilator
in spite of donepezil treatment in our study were not
readily clear. Although it seems patients apparently had a
depressed ventilatory drive initially, but possible inadequate
resolution of the illness that had caused mechanical venti-
lation and/or progress of new problem could incorporate
to weaning failure in few patients.icult to wean patients 
 response who fulfilled 
a
2 patients of enrolled subjects died
 study 
11 patients experienced successful weaning
y follow up. Eleven out of 16 difficult to wean patients who
Table 1 Demographic and clinical characteristics of the patients with donepezil intervention to facilitate weaning










1 73 M COPD exacerbation, pneumonia,
pulmonary edema
2 10 28 S but re-intubated D
2 26 M Opioid intoxiction, seizure 2 30# 6 S A
3 55 M COPD exacerbation, PTE, pneumonia 2 5 4 S A
4 73 M COPD exacerbation, Pneumonia 2 5 8 S D
5 72 M Brain tumor, PTE, pneumonia 2 10 15 F' D
6 64 F Abdominoplasty, PTE 2 19 9 S A
7 80 F PTE, dyspnea, pneumonia,
pulmonary edema
1 18 8 S A
8 68 M Arrest, pneumonia 3 60# 6 S A
9 41 F Arnoldikiary, pneumonia 2 25# 13 S A
10 81 F cholecystectomy 2 32# 10 S A
11 78 M COPD exacerbation, pneumonia 3 33# 17 F' A
12 68 M CVA, pneumonia 3 65# 27 S A
13 67 M PTE, dyspnea, pneumonia 3 60# 4 S A
14 81 M Massive pleural effusion, pneumonia,
pulmonary edema
3 57# 15 F' A
15 24 M Multiple trauma, pneumonia 1 57# 21 S A
16 46 M Cerebral tumor, pneumonia, PTE 1 33# 15 F' A
αBefore donepezil initiation.
*From initial donepezil treatment until outcome measurement.
#Tracheostomy tube used for mechanical ventilation.
A, alive; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; D, died; F, female; F', failure; MV, mechanical ventilation; M, male; NA, not
applicable and excluded; PTE, pulmonary thromboembolism; S, success.
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ing failure manifested ultimately by rising in PCO2 [26].
Weaning failure in our study might be contributed to
muscle fatigue during donepezil intervention. Because as
mentioned in results, mean PCO2 rose in patients with
unsuccessful weaning in this period. If fatigue developed
during donepezil treatment, further stimulation of the
respiratory muscles with donepezil would have inevitably
made the fatigue worse and patients would have weaning
failure or required re-intubation.
In addition, in a patient with cervical tumor, phrenic
nerve was involved and patient had also peripheral
neuropathy. Since, diaphragm muscle is primarily
innervated by the phrenic nerve, partial damage of
that in surgical removal of cervical tumor could be a
reason for failed response to donepezil intervention.Table 2 Comparison of clinical parameters in patients with su
Parameters Successful w
(N = 11)
Age (Mean ± SD) 58.8 ± 20.1
duration of mechanical ventilation (Mean ± SD) 34.2 ± 22.6
duration of donepezil treatment (Mean ± SD) 10.6 ± 7.3
*Mann–Whitney U test was performed.Moreover, metabolic alkalosis may be another causa-
tive factor for re-intubation of the first patient in our
study because compensatory hypoventilatory response to
metabolic alkalosis disposed patient to weaning failure or
re-intubation [27]. Some studies maintained pH less than
7.4 during the time of active weaning [28].
Most of patients had history of pneumonia in our study
which justified extubation failure and predisposition of
them in difficult-to-wean condition. Pneumonia at the
initiation of ventilation was one of the best predictors
of extubation failure for patients following a successful
SBT [29].
Cholinergic stimulation to develop respiratory coordin-
ation [30], increasing neuromuscular transmission and
improving the effectiveness of upper airways muscles are
some reasons which donepezil can accelerate weaning [31].ccessful and unsuccessful weaning trial
eaning Unsuccessful weaning p-value
*(N = 5)
70.0 ± 14.0 0.22
28.6 ± 19.6 0.83
18.0 ± 5.7 0.03
Figure 2 Variation of Arterial blood gas during donepezil treatment. Variations in arterial PH, PO2, PCO2, HCO3 and oxygen saturation were
demonstrated in part A, B, C, D and E respectively. For each patient the first reported parameter was related to donepezil initiation day and the
last one demonstrated that parameter on weaning day or until donepezil treatment was continued in cases of weaning failure. Patients with
number 5, 11, 14 and 16 had unsuccessful attempts for weaning.
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response to hypoxia by acting upon carotid body and
stimulate respiratory center, but also play an important role
in the neural control of respiration [31-33]. In addition,
beneficial effects of cholinergic drugs to increase saliva
secretion can reduce collapsibility of upper airways and
contribute in this result [34]. Although different mecha-
nisms can explain the beneficial effect of donepezil to
expedite weaning but the exact mechanism is not clear.
By considering these mechanisms, donepezil facilitated
the weaning of most patients in our study. We concludethat ABG parameters can be valuable factors to predict
patient response to donepezil intervention. As our results
also showed, decrease of PCO2 and HCO3 during
donepezil steady state would give us good news about
positive response of donepezil and possibly successful
weaning trial in near future. Conversely, increase or
unchanged PCO2 during steady state of donepezil
could promote clinicians to seek for other reasons of
weaning failure such as muscle fatigue. However,
because of small sample size analyzed in this study
differences in ABG parameters between two groups
Table 3 Arterial blood gas parameters before and after donepezil intervention
ABG parameters Group Mean ± SD p-value
Successful weaning (N = 11) PH Before 7.39 ± .076 0.96
After 7.38 ± .047
PO2 Before 73.2 ± 27.1 0.84
After 75.5 ± 15.3
PCO2 Before 48.2 ± 20.6 0.23
After 42.8 ± 11.3
HCO3 Before 27.4 ± 8.0 0.19
After 25.1 ± 7.4
PO2 saturation Before 89.9 ± 12.1 0.29
After 94.49 ± 2.4
Unsuccessful weaning or re-intubation (N = 5) PH Before 7.46 ± 0.15 0.19
After 7.40 ± 0.06
PO2 Before 54.7 ± 20.9 0.67
After 68.2 ± 19.6
PCO2 Before 35.5 ± 13.0 0.192
After 39.8 ± 7.0
HCO3 Before 23.5 ± 7.1 0.132
After 23.9 ± 6.1
PO2 saturation Before 92.4 ± 2.7 0.99
After 91.7 ± 7.8
PCO2: carbon dioxide, PO2: Partial pressures of oxygen, SO2: hemoglobin oxygen saturation and SD: standard deviation.
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significant.
Various pharmacokinetic parameters in population
study and contribution of different factors in weaning
process might be the reasons of diverse time needed for
donepezil treatment to achieve its response goal during
the study. As expected, mean duration of donepezil until
successful weaning was 12 days which was parallel to
the time required for donepezil to receive its steady state
[20]. However, clinical benefit of donepezil may occur
before or after steady state of donepezil. Therefore we
suggest if weaning is not facilitated during 2 weeks of
donepezil initiation and clinician do not find any other
factor for this failure, patient may benefit from 4 weeks
therapy. This study protocol justify the significant higher
duration of donepezil treatment in patients who failed
weaning trial compared to those with successful weaning
outcomes.
Finally, potential limitations of the present study
should be mentioned. First, however patients ruled out
for other potential barriers of weaning in our study but
other reasons of weaning failure might not be com-
pletely resolved or some new barriers evolved during the
study. So, outcome of weaning failure in our popula-
tion is not necessarily or primarily related to respira-
tory drive problem which is discussed in patients withunsuccessful weaning trial. Another limitation which
should be pointed out is that relatively small number
of studied patients. Despite more than 1 year study
duration and inclusion of consecutive patients in two
centers; only limited number of patients entered the
study according to inclusion and exclusion criteria. A
non-randomized design of this study without control
group is the third limitation. Therefore, these results
require further confirmation with larger controlled
clinical trials to clarify and establish donepezil role in
the management of difficult-to-wean patients. Add-
itional studies should be conducted to compare the ef-
ficacy of donepezil with other respiratory center stimulants
such as doxapram or cholinergic drugs to facilitate weaning
in difficult-to-wean patients with respiratory drive
problem. Moreover, the effect of donepezil on weaning of
patients with different diagnoses can be evaluated in
future studies.
Conclusion
According to safety consideration and previous study in
obstructive sleep apnea (OSA) we evaluated 10 mg of
donepezil during 2–4 weeks in our study [19]. In accord-
ance with our findings, donepezil also supported breathing
regulation in OSA patients [19]. To the best of our
knowledge, this is the first study in which donepezil was
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patients in order to expedite the weaning.
However ventilator drive failure uncommonly exists
on the list of reversible causes of weaning problem, but
it may prolong mechanical ventilation and lead impaired
weaning. We think this condition may be overlooked by
the other factors which contribute to weaning failure
and may remain unrecognized. Our results showed
donepezil could be considered as useful treatment option
in this condition.
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